Indications |
Oral Postherpetic neuralgia Adult: 75-150 mg bid. May increase up to 600 mg/day in patients with ongoing pain and can tolerate 300 mg/day. Renal impairment: Dosage adjustment is required. Patients undergoing haemodialysis should receive a supplementary dose of 25-100 mg immediately after each 4-hr haemodialysis session.
Oral Adjunct in partial seizures Adult: 150-600 mg/day. Should be given in 2-3 divided doses. Max dose: 600 mg/day, Renal impairment: Dosage adjustment is required. Patients undergoing haemodialysis should receive a supplementary dose of 25-100 mg immediately after each 4-hr haemodialysis session.
Oral Fibromyalgia Adult: Initiate at 75 mg bid. May increase to 225 mg bid for patients who do not experience sufficient benefit with 300 mg/day. Renal impairment: Dosage adjustment is required. Patients undergoing haemodialysis should receive a supplementary dose of 25-100 mg immediately after each 4-hr haemodialysis session.
Oral Anxiety Adult: Initiate at 150 mg daily. May increase at wkly intervals in steps of 150 mg. Max dose: 600 mg daily. Renal impairment: Dosage adjustment is required. Patients undergoing haemodialysis should receive a supplementary dose of 25-100 mg immediately after each 4-hr haemodialysis session.
Special Populations: The dose should be adjusted in patients with reduced renal function based on creatinine clearance. CrCl of at least 60 mL/min: 50-100mg tid. |
||||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity. Pregnancy, lactation. Driving or working with machines, or do other dangerous activities. | ||||||||||||||||||||||||||||||||
Warnings / Precautions |
Discontinue treatment if patients develop severe angioedema. Withdraw treatment gradually over at least 1 wk. May cause peripheral oedema. Regular vision check is recommended. May decrease platelet count and prolong PR interval. | ||||||||||||||||||||||||||||||||
Adverse Reactions |
Dizziness, drowsiness, visual disturbance (including blurred vision, diplopia), ataxia, dysarthria, tremor, lethargy, memory impairment, euphoria, wt gain, constipation, dry mouth, peripheral edema, depression, confusion, agitation, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, excessive salivation, sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, neutropenia, 1st ° heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis. | ||||||||||||||||||||||||||||||||
Drug Interactions |
Concurrent use with oxycodone, lorazepam and ethanol may increase the CNS effects. See Below for More pregabalin Drug Interactions |
||||||||||||||||||||||||||||||||
Mechanism of Actions |
Pregabalin is an analog of the neurotransmitter GABA. It binds potently to the alpha2-delta subunit resulting in modulation of Ca channels and reduction in the release of several neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P. Absorption: Rapidly absorbed after oral doses. Peak plasma concentrations are achieved within 1.5 hr. Distribution: Not bound to plasma proteins. Metabolism: Negligible metabolism. Excretion: About 98% excreted unchanged in urine. Elimination half life: about 6.3 hr. |
||||||||||||||||||||||||||||||||
Administration |
May be taken with or without food. |
||||||||||||||||||||||||||||||||
Storage Conditions |
Oral: Store at 25°C. | ||||||||||||||||||||||||||||||||
ATC Classification |
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics. | ||||||||||||||||||||||||||||||||
Storage |
Oral: Store at 25°C. | ||||||||||||||||||||||||||||||||
Available As |
|
Pregabalin
Post Review about Pregabalin Click here to cancel reply.
Drug - Drug Interactions of Pregabalin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.